Compumed Stock Net Income
| CMPD Stock | USD 4.50 0.27 6.38% |
As of the 8th of February, CompuMed shows the Downside Deviation of 5.54, mean deviation of 3.95, and Risk Adjusted Performance of 0.1217. CompuMed technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm CompuMed information ratio, as well as the relationship between the value at risk and expected short fall to decide if CompuMed is priced correctly, providing market reflects its regular price of 4.5 per share. Given that CompuMed has jensen alpha of 0.753, we suggest you to validate CompuMed's prevailing market performance to make sure the company can sustain itself at a future point.
CompuMed's financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing CompuMed's valuation are provided below:CompuMed does not presently have any fundamental signals for analysis. This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools. CompuMed |
CompuMed 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to CompuMed's pink sheet what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of CompuMed.
| 11/10/2025 |
| 02/08/2026 |
If you would invest 0.00 in CompuMed on November 10, 2025 and sell it all today you would earn a total of 0.00 from holding CompuMed or generate 0.0% return on investment in CompuMed over 90 days. CompuMed is related to or competes with Healthlynked Corp, Mosaic Immunoengineerin, and Vycor Medical. CompuMed, Inc., an enterprise telemedicine solutions company, provides clinical care services for patients and medical f... More
CompuMed Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure CompuMed's pink sheet current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess CompuMed upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 5.54 | |||
| Information Ratio | 0.1245 | |||
| Maximum Drawdown | 34.52 | |||
| Value At Risk | (7.08) | |||
| Potential Upside | 9.84 |
CompuMed Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for CompuMed's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as CompuMed's standard deviation. In reality, there are many statistical measures that can use CompuMed historical prices to predict the future CompuMed's volatility.| Risk Adjusted Performance | 0.1217 | |||
| Jensen Alpha | 0.753 | |||
| Total Risk Alpha | 0.2248 | |||
| Sortino Ratio | 0.1271 | |||
| Treynor Ratio | 2.03 |
CompuMed February 8, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.1217 | |||
| Market Risk Adjusted Performance | 2.04 | |||
| Mean Deviation | 3.95 | |||
| Semi Deviation | 3.67 | |||
| Downside Deviation | 5.54 | |||
| Coefficient Of Variation | 712.21 | |||
| Standard Deviation | 5.65 | |||
| Variance | 31.95 | |||
| Information Ratio | 0.1245 | |||
| Jensen Alpha | 0.753 | |||
| Total Risk Alpha | 0.2248 | |||
| Sortino Ratio | 0.1271 | |||
| Treynor Ratio | 2.03 | |||
| Maximum Drawdown | 34.52 | |||
| Value At Risk | (7.08) | |||
| Potential Upside | 9.84 | |||
| Downside Variance | 30.66 | |||
| Semi Variance | 13.46 | |||
| Expected Short fall | (6.20) | |||
| Skewness | 0.943 | |||
| Kurtosis | 2.59 |
CompuMed Backtested Returns
CompuMed appears to be risky, given 3 months investment horizon. CompuMed secures Sharpe Ratio (or Efficiency) of 0.16, which signifies that the company had a 0.16 % return per unit of risk over the last 3 months. By analyzing CompuMed's technical indicators, you can evaluate if the expected return of 0.92% is justified by implied risk. Please makes use of CompuMed's Risk Adjusted Performance of 0.1217, downside deviation of 5.54, and Mean Deviation of 3.95 to double-check if our risk estimates are consistent with your expectations. On a scale of 0 to 100, CompuMed holds a performance score of 12. The firm shows a Beta (market volatility) of 0.39, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, CompuMed's returns are expected to increase less than the market. However, during the bear market, the loss of holding CompuMed is expected to be smaller as well. Please check CompuMed's total risk alpha, expected short fall, period momentum indicator, as well as the relationship between the value at risk and rate of daily change , to make a quick decision on whether CompuMed's price patterns will revert.
Auto-correlation | 0.44 |
Average predictability
CompuMed has average predictability. Overlapping area represents the amount of predictability between CompuMed time series from 10th of November 2025 to 25th of December 2025 and 25th of December 2025 to 8th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of CompuMed price movement. The serial correlation of 0.44 indicates that just about 44.0% of current CompuMed price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.44 | |
| Spearman Rank Test | 0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.05 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Based on the recorded statements, CompuMed reported net income of 84.95 K. This is 99.98% lower than that of the Health Care Technology sector and significantly higher than that of the Health Care industry. The net income for all United States stocks is 99.99% higher than that of the company.
CompuMed Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses CompuMed's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of CompuMed could also be used in its relative valuation, which is a method of valuing CompuMed by comparing valuation metrics of similar companies.CompuMed is currently under evaluation in net income category among its peers.
CompuMed Fundamentals
| Return On Equity | -0.3 | |||
| Return On Asset | -0.13 | |||
| Profit Margin | (0.02) % | |||
| Operating Margin | (0.08) % | |||
| Current Valuation | 4.12 M | |||
| Shares Outstanding | 1.11 M | |||
| Price To Earning | (8.36) X | |||
| Price To Book | 36.30 X | |||
| Price To Sales | 2.43 X | |||
| Revenue | 2.31 M | |||
| Gross Profit | 879 K | |||
| EBITDA | (45 K) | |||
| Net Income | 84.95 K | |||
| Cash And Equivalents | 4 K | |||
| Total Debt | 24.91 K | |||
| Debt To Equity | 1.28 % | |||
| Current Ratio | 1.05 X | |||
| Book Value Per Share | 0.11 X | |||
| Cash Flow From Operations | 175.43 K | |||
| Earnings Per Share | (0.01) X | |||
| Target Price | 2.05 | |||
| Beta | 0.95 | |||
| Market Capitalization | 4.12 M | |||
| Total Asset | 835.02 K | |||
| Retained Earnings | (37.15 M) | |||
| Working Capital | 144 K | |||
| Current Asset | 392 K | |||
| Current Liabilities | 248 K | |||
| Z Score | 39.4 | |||
| Net Asset | 835.02 K |
About CompuMed Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze CompuMed's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of CompuMed using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of CompuMed based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Other Information on Investing in CompuMed Pink Sheet
CompuMed financial ratios help investors to determine whether CompuMed Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in CompuMed with respect to the benefits of owning CompuMed security.